Shares in Hungarian pharmaceutical company Gedeon Richter Nyrt. dropped after reporting disappointing results in a clinical trial of its Cariprazine drug.
The results showed that flexible doses of cariprazine didn’t separate significantly from a placebo as an add-on treatment in adults with major depressive disorder, Richter and partner Allergan Plc said in a joint statement on Friday. The drug has already been introduced in the U.S. after approval for the treatment of bipolar mania and schizophrenia last year.
